Triple Negative Breast Cancer Clinical Trial
Official title:
A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Cyclosporin A on Triple Negative Breast Cancer With Defective DNA Repair
This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer with high g-H2Ax (gamma H2AX antibodies) comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Status | Not yet recruiting |
Enrollment | 24 |
Est. completion date | July 2027 |
Est. primary completion date | July 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants may be female or male who are 18 years old or older. Ability to consent to treatment - patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. - Previously untreated invasive breast cancer determined by a core needle biopsy. - Prior, unrelated, breast cancer is allowed. - Stage I-III breast cancer will be included that are Estrogen receptor and or progesterone receptor 0-10%, human epidermal growth factor receptor 2 (HER2) negative defined as per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP guidelines). HER2 of 2+ on Immunohistochemistry (IHC) should have a ratio of less than 2.0 on fluorescence in situ hybridization (FISH) testing to be considered HER2 negative - Patients must have low or negative RAD51 immunohistochemistry (defined as median <5 foci per nucleus after measuring at least 200 cells) - Patients must be able to take oral medications. Patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug. - Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (ß-hCG) pregnancy test result within 14 days prior to the first dose of CsA. - Women of childbearing potential and men should have an adequate mode of contraception to be eligible for this trial. - Patients must be eligible for surgical resection of their breast cancer or repeat biopsy after completing treatment. - Patients must have a complete history and physical examination within 30 days prior to registration. - Patients must have a performance status of Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2. - Tissue block of initial biopsy specimen is available. - Patient may not be concurrently enrolled in another investigational drug treatment study. Exclusion Criteria: - Renal impairment defined as estimated glomerular filtration rate (EGFR) <30 - Hepatic impairment as judged by clinical investigator or bilirubin >2 - As judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness, or social condition that would limit compliance with study requirements - Known hypersensitivity to CsA - Current use of calcium channel blockers, antifungals, azithromycin, clarithromycin, erythromycin, methylprednisolone, allopurinol, amiodarone, metoclopramide, bromocriptine, colchicine, oral contraceptives, nafcillin, rifampin, phenytoin, octreotide, phenobarbital, carbamazepine, St John's Wort, HIV protease inhibitors - Inflammatory breast cancer - Uncontrolled hypertension - Pregnant or breast-feeding women. As there have been no well-controlled studies conducted with pregnant women to determine the effect of CsA on the fetus. However, there have been clinical reports of congenital malformations associated with the use of the drug. - Patients who will receive neoadjuvant chemotherapy for their triple negative breast cancer are not eligible for this clinical trial. |
Country | Name | City | State |
---|---|---|---|
United States | Mays Cancer Center, UT Health San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Virginia G. Kaklamani |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ki67 Expression | To evaluate changes in Ki67 expression after administration of CsA for 14-30 days in triple negative breast cancer tumors. | 6 weeks | |
Secondary | Changes in g-H2Ax | To determine if CsA at a dose of 5mg/kg orally daily for 14- 30 days shows a change in g-H2Ax of triple negative breast cancer. | 6 weeks | |
Secondary | Changes in apoptosis markers | To evaluate change in apoptosis markers by Tunnel assay after administration of CsA for 14-30 days in triple negative breast cancer tumors. | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05174832 -
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Withdrawn |
NCT03634150 -
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03348098 -
Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer
|
Phase 2 | |
Completed |
NCT04032080 -
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02427581 -
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
|
Phase 1 | |
Recruiting |
NCT03165487 -
Comparison of the Breast Tumor Microenvironment
|
||
Completed |
NCT02225470 -
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
|
Phase 3 | |
Recruiting |
NCT04452370 -
Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04758780 -
Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients
|
Phase 2 | |
Withdrawn |
NCT04268693 -
Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer
|
||
Withdrawn |
NCT03982173 -
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT02685657 -
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT01918306 -
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01276899 -
Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
|
||
Completed |
NCT00998036 -
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05309655 -
Cardiac Outcomes With Near-Complete Estrogen Deprivation
|
Early Phase 1 | |
Active, not recruiting |
NCT03267316 -
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
|
Phase 1/Phase 2 |